Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We got conned by a Shinister
Call him pick his brain.See if he,s nice?
Where's the SEC? They should protect shareholders from people like Shinn. Telling certain investors that news is coming for years to entice them to buy is down right unethical. Well: How do I get ahold of this guy and what can I expect when I call him.
Thanks
No no contact for couple months.
Well: Have you spoken to this psycho Shinn lately? He must of learned how to rip off people when he was working for the prison system
Shinn must be selling.....what comes around goes around
If I were Shinn, I would put out a PR soon to cover his ass and just give an update.
If I told you what he said to me three years ago it would blow your mind.
If I told you what he said to me three years ago it would blow your mind.
Sounds like a nut case!
Every conversation I had with Shinn since 2013 he said news is coming.. NOTHING IT'S NOW 2015.
No buys no sales today? No volume...Those buys must of meant nothing the last couple days??
Is Shinn just a pathological liar?
Question is, why did someone buy 100 shares at .002? Twenty cents...sometimes it's an esoteric message
Why only 19,000 are there no more to buy at $.002? If something is going on what a bargain.
Thank for the information. Something looks like it's going on??? Let's hope!!
Summary of Grey Sheet Trading
Grey sheet trading should be treated with the highest suspicion. Remember, Gray Sheets have the least regulation and very little history in general. I guess they are not under any SEC disclosing requirements, so Shinn can have his way without any consequences. Shareholders get screwed. Information is difficult to find if not impossible for such stocks, so determining the value, if any, is next to impossible. These stocks are highly illiquid. However, once in awhile, a Grey stock is bought out or comes out with huge news and the stock price explodes. They keep under the radar being on the Grey Market. Let's hope that's the case with ATKJ. Another possible good sign is that it's trading but who knows in the wacky world of the Grey Market
Who knows, could it be Shinn? Sorry to say Well but no bid no ask, no financials since the incepetion and no PR for 5 years. Stick a fork in it...it's been over for years and Shinn is full of BS in my opinion!
Why is someone buying? What do they know???
I think Shinn might be in big trouble. If he has been telling shareholders "news is coming" for years, that is a violation of the SEC. CEO's should only put a PR and not tell individual investors news is coming. That could be considered inside information and at the least, it could be considered trying to manipulate the stock price. What Well has stated, Mr. Shinn does not seem to be functioning with a full deck. I hope Mr. Shinn has not been lying to the shareholders but as stated, he's been telling shareholders news was coming soon and no news for years. Something is definitely not above aboard. GL AIMHO
Probably Shinn buying to entice people to invest. This company has all the signs of a dead company. Keep those emails from Shinn for later on
30,000 shares have not traded since Dec 2013....I'm surprised it's still trading..that in itself is good news.
now there's over 30,000 shares traded what's going on?
Another 10,000 shares traded..what's up? Most trades for months..Hmmmm...is their life?
Just got a alert from my brokerage company...up 100%..hmmmm. I got into this stock because a few of my friends suggested it would be an excellent invested and yes we are still friends but Well, they stated the same thing regarding getting emails from Shinn for years that news was coming and they have kept all their emails.....so class action lawsuit, who knows but if + news comes out, all is forgiven. Maybe the 100 share buy was a message to other MM's/whoever that it's time to buy because news is coming..let's hope.
Did you buy that 100 shares? At least it does trade...still no bid and ask....still shady!
It sounds like Ron has some psychological issues. Well: how would you go about reporting Shinn and his company to the SEC? I believe shareholders have some rights re: companies that don't report for years and I hope you've kept any emails from Shinn promising news over the years. Maybe a class action lawsuit can happen. Alot of shady people and companies in pennyland. I wish the SEC would close them down
About 2 months ago I had a conversation with Dr Shinn about the future of Artec. Later on that day I gave him a call back and expressed my feelings about that conversation. I didn't feel that Artec had much of a future, so what does he do because I disagreed with him? He threatened to file a restraining order against me if I ever called him again. That man is a control freak. I don't believe Artec has any future with Shinn at the helm. It's time for us shareholders to fight for a new company president. Tubercin could save lives but I don't believe its under the Shinn regime. That man is a control freak and not a very nice guy.I cant stand him.
He's been telling me for years every couple of months something is going to happen "any day now". I heard this every time I converse with him. Nothing ever happens. Why does he tell us this? Is he trying to get one of us to buy more shares, or is he full of shi%? I think he's full of it.I still don't believe even after 8-9 years Shinn has any hope to get Tubercin to market.
Can't sell, no bid or ask.....got us by the %$^&....worthless security. I understand now why the name Shinister was used....what a scam..to bad Shinn isn't making any $$$$$ either
This compnay is worthless...no trading, no bid no ask.....it will probably be delisted soon....I agree, stay away..it's a bogus company in my opinion!!!!!!!
I would strongly suggest potential investors stay away from this company. They have not put out a PR for over 4 years and no financial statements since their inception over 9 years ago. Tubercin has been out for like 30 years and has not amounted to anything.....STAY AWAY. OIMHO
PS I have no idea how the SEC can even have this company listed...they should delist it...however, I don't think you can even trade it
In the past, investors/shareholders use to call Ron the "SHINISTER" and now I know why.
I do not think you can trade this stock anymore!!!
GL on buying or selling...Shinn is a joke
I have to agree with Go4....Shinn told me years ago news was right around the corner...never happened of course. Spoke to him once and seemed very paranoid...maybe some psychological issues but who knows. I think the company will file BK soon and tubercin is salt and sugar. Oh well, another penny stock does not pay off....typical in pennyland....hopefully, lesson learned this time.
Sorry but it ain't going to happen..Shinn is full of BS...tubercin would have been bought up by the big Pharma companies a long time ago if it tubercin was the real deal. Future investors, do not buy this stock, this company is full of holes... IMHO. I wish the SEC would shut these companies down for the protection of investors..AIMHO
Your right about a lot your saying. News hasn't been put out in years,and other fact's,but I still believe Tubercin will come to market one of these day's.
Is Shinn still pumping you with hype? They haven't put out a PR for years and no financials for years...tubercin has been out there for 30+ years and hasn't gone anywhere....come on, get real. If your so sure than prove it by buying, I doubt you're that comfortable with this company but I'll watch and see if you buy but I doubt it
It's going to cure people and save lives...
Don't be surprised if you see this stock go to the moon VERY soon!! Tubercin/Welme have a tremendous future. Beware sellers......
This company and their product is a pipedream....more of a chance they will close down soon.......do not invest...waste of your $$$$ IMHO
What do you mean: how much time nobody knows.
I haven't been around this board for a while. What is going to happen with tubercin?
What is going to happen with this?
It's just matter of time? How much time nobody knows?
I think we have been had...:(
A DRUG BY MERCK PHARMACUTICAL THAT WORKS LIKE TUBERCIN.....
After months of anticipation, the FDA has approved a new type of cancer drug that is designed to use the body’s own immune system to combat tumors and, in the process, may generate billions of dollars in sales. Known as Keytruda, the medicine is part of an anticipated wave of drugs that could transform cancer treatment and create a huge market for the pharmaceutical industry.
The drug will cost $12,500 a month and Merck says the median usage is 6.2 months, which works out to a $77,500 price tag, or $150,000 on annualized basis.
Keytruda is the first so-called PD-1 inhibitor to become available in the U.S. This type of drug blocks a protein called programmed death receptor 1, which acts as a brake on certain immune system cells and prevents them from attacking healthy tissue. Cancer cells can escape death by latching onto PD-1; the inhibitors block the interaction at the site of the tumor, releasing the brake that destroys the cancer.
The drug is intended for use following treatment with Yervoy, another immunotherapy treatment that works differently. The approval followed an accelerated review of clinical trial data from a relatively early-stage study. This was an unusual move, but it reflected intense interest in the medical community, which is excited, generally, about PD-1 inhibitors and the potential for combating other forms of cancer.
“PD-1 is truly a game change. It’s active in a way that other drugs are not,” Lynn Schuchter, a medical oncologist who heads the melanoma program at the Abramson Cancer Center at the University of Pennsylvania and who assisted in clinical trials for the Merck drug, tells The Wall Street Journal. “And what’s been interesting is the activity of PD-1 beyond melanoma. It looks to be active in bladder and renal and lung cancer.”
Indeed, physicians are optimistic about PD-1 drugs because they appear to induce relatively high rates of tumor shrinkage and prolong average survival beyond historical norms in clinical studies. And researchers say the side effects associated with the drugs appears to be manageable. Roche and Bristol-Myers Squibb BMY +0.04% are among the drug makers working to develop these medicines.
Some analysts believe total annual sales of all cancer immunotherapies could reach about $32 billion by 2025, assuming still more drugs are approved to treat difference cancers. Leerink analysts estimate that the new Merck drug alone could generate annual sales of more than $6 billion by then. Keytruda will cost $12,500 a month and the median length of use is estimated to be 6.2 months.
A competing PD-1 inhibitor was launched this month in Japan with a $143,000 price tag for a year’s treatment for the average patient. The drug, which is marketed by Ono Pharmaceutical and Bristol-Myers, is expected to be reviewed by the FDA in the next few months. Other PD-1 drugs are expected to cost a similar amount, which could fuel more debate about the affordability of new medicines.
According to the National Cancer Institute, an estimated 76,100 Americans will be diagnosed with melanoma and 9,710 will die from the disease this year. Keytruda, by the way, is the sixth new melanoma treatment to be approved since 2011, although the FDA noted that drugs have different mechanisms of action.
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5055
|
Created
|
07/08/05
|
Type
|
Free
|
Moderators |
Authorized: 300 million
Issued: 100 million
Float: 12-17 million
Shinn: 54 million
Tai Ho Chung: 8 million
CC Chung: 4 million
David Chai: 4 million
Bank (?): large holding (?)
Website
Pharmaceutical Firm, ARTEC, Inc., Reports Moving On In The Development Of An Improved Tubercin™ And The Testing Of HIV/AIDS Human Patients In Africa
27 May 2010 - 22:00 PDT
ARTEC, Inc., (Pink Sheets: ATKJ), has improved Tubercin T-5 an immunostimulant. In the last two years, Artec asserts that Tubercin™ has improved significantly and tested in Africa, in the company's opinion, with positive results on human patients afflicted with HIV/AIDS. Under strict confidential conditions, the results received were most encouraging. Artec is engaged in full pursuit of obtaining FDA registration of Tubercin™ in Africa.
With ample funding, the success of Artec is within reach. The steady support of Artec's shareholders and associates has fostered its accomplishments. Artec thanks all the aforementioned for their loyalty and support.
Artec Inc. is a small entrepreneurial pharmaceutical company in a very competitive field of "Discovering Medicine" to curb HIV/AIDS and cancer. The costs involved are very steep and the challenges bordering on insurmountable. Artec has succeeded in coming this far where, in the company's opinion, significant research for many years and billions of dollars spent have not. Artec thanks its partner Dr. Tai Ho Chung, his son C.C. Chung and Kyungpook National University (Seoul, Korea) for the patented baseline research prototype, Tubercin™. T-5. Artec looks forward to working together with Dr. Chung and C.C. Chung to bring this improved Tubercin to the world. Artec's Leading Scientist, Dr. J.K. Park and his associates have also helped, in the company's view, improve the efficacy of the new Tubercin. Artec also thanks Dr. J.K. Park and everyone working under his leadership and in unison with his association with them.
Artec is serious about the future. The firm has recently explored such issues as Permanent Headquarters; High Volume Manufacturing of Tubercin; and Developing a Vaccine for Prevention of HIV/AIDS yet Impacting HIV/AIDS and cancer. Artec's progress in the next few months is considered critical for continued successes.
Artec is resolved to bring Tubercin to the market in the near future. Artec appreciates the continued support. The company will disclose more appropriate and specific information in the future. The confidential agreements do not afford Artec the liberty to disclose specific information at this time.
Source
ARTEC, Inc.
http://www.medicalnewstoday.com/articles/190138.php
Pharmaceutical Firm, ARTEC, Inc., Announces Testing Launch of TUBERCIN(TM) -- Mission Focus is on the Testing of HIV/AIDS & Tuberculosis Patients in South Africa
Monday September 24, 2007 7:01 am ET
OKLAHOMA CITY--(BUSINESS WIRE)--ARTEC, Inc., (Pink Sheets: ATKJ - News), visionary pharmaceutical firm, has acquired the preliminary outline to be used for the testing protocol from a sponsoring scientific group in South Africa for TUBERCIN(TM), a revolutionary polysaccharide compound to be used as an HIV/AIDS and ANTI-CANCER immunostimulant.
"We are grateful to further test the medicinal impact of TUBERCIN(TM) in South Africa on their suffering patients," said Mr. Gerry Knight, Executive Vice-President of ARTEC, Inc. "Their dedicated partnership is enabling the launch testing of an immunostimulant we believe will greatly impact the devastation of HIV/AIDS, Tuberculosis and cancer worldwide. The continued assistance from our shareholders will also uphold our commitment to speedily developing TUBERCIN(TM) as a treatment that could soon bring hope to the millions suffering."
Early in October 2006, Dr. Ronald Shinn, President and Board of Directors Chairman of ARTEC, Inc. arrived in South Africa at the invitation of a group of prominent business and professional South Africans. Although previous in depth communications had occurred, the trip enabled both sides the face-to-face opportunity to explore the use of TUBERCIN(TM) on the devastating impact of HIV/AIDS in Africa. The problem of AIDS is horrendous especially when witnessing it first hand.
The Desperate Need for Relief of HIV/AIDS and Tuberculosis in South Africa is currently experiencing one of the most severe HIV/AIDS epidemics in the world. As reported by the World Health Organization, HIV and Tuberculosis form a lethal combination each speeding the other's progress. By the end of 2005, there were five and a half million people living with HIV in South Africa, and almost 1,000 AIDS deaths occurring every day.
The Company, together with the cooperation of Mr. Rodney Watson, Director of ARTEC, Inc. South Africa, has assembled a team of scientific personnel necessary for the South Africa FDA project. Emerging as the chief scientist for ARTEC, Inc. is Dr. Shawn Pruitt from the U.S.A. Dr. Pruitt and his colleagues have been working diligently in the development of information and materials on research needed for this project.
Recently, ARTEC, Inc. received the preliminary outline of the Testing Protocol to be used from the sponsoring scientific group in South Africa. It is advocating the testing of TUBERCIN(TM) on human patients in the hospital afflicted with AIDS and Tuberculosis. The testing will begin with under 100 patients. ARTEC, Inc. is working on this project as high priority and will provide more information as it becomes known.
In addition to working on the FDA project, Artec, Inc. has initiated direct contact with JSE Limited, formerly the Johannesburg Securities Exchange, and is in the process of establishing membership.
President Dr. Ronald Shinn has made a commitment, on behalf of ARTEC, Inc. to raise the necessary funding to combat HIV/AIDS in Africa and world wide. The Company appreciates the continued shareholders support!
ARTEC, Inc. intends to release further information on the progress of its product developments and integration. For more information on ARTEC, Inc., visit http://www.artec-inc.net .
Contact:
ARTEC, Inc.
Dr.Ronald Shinn 916-428-3458
http://www.ARTEC-Inc.net
Shapiro's Tubercin-virus patent filing - (WO/2006/078369)
Prior Art showing this to be old and NOT inventive
Protest info here
Hard to Treat Diseases v. Ronald Shinn 05-14737 04-80010 CV-DTKH 12-12-2006
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |